ArticleBMC psychiatry2025
SSRI-induced modulation of cytokines, barrier permeability, and BDNF in adolescent depression.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence links immune activation to antidepressant response in adolescents with major depressive disorder (MDD). We examined how depressive symptoms, quality of life (QOL), and blood markers of inflammation, blood–brain barrier (BBB) integrity, and gut permeability change following antidepressant treatment in this population.
methodsTwenty-six adolescents with MDD were evaluated at baseline (pre-treatment), 12 weeks, and 24 weeks after starting therapy. Depression and anxiety were measured by the Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA). QOL was assessed with the QOL Scale for Children and Adolescents (QLSCA) and an adolescent social support instrument. Serum levels of IL-1β, TNF-α, IL-6, IL-4, S100β, claudin-5, LBP, I-FABP, and brain-derived neurotrophic factor (BDNF) were quantified.
resultsAt baseline, pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and IL-4 strongly correlated with BBB (S100β, claudin-5) and gut-permeability (I-FABP) markers. IL-4 levels rose significantly and were associated with reduced anxiety (HAMA: r = −0.48, p < 0.05) and better QOL (QLSCA: r = 0.57, p < 0.01). BBB integrity and gut-permeability markers remained stable. In responders only, BDNF increased at 12 weeks (p < 0.05) and IL-8 rose at 24 weeks (p < 0.05), suggesting their involvement in treatment efficacy.
conclusionsAntidepressant therapy in adolescents with MDD is accompanied by dynamic elevations in IL-4, IL-8, and BDNF that parallel clinical improvement and enhanced QOL. These biomarkers warrant further study to develop more targeted interventions for adolescent depression. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.